Safety
Most common adverse events are acute infusion related events
Severe infections are seen in 28% of patients including those due to opportunistic pathogens
Hematologic toxicity which can be severe emerges on treatment in some patients
Reasonable and manageable safety profile in this immunocompromised, refractory disease population